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Abstract
CD1 molecules are glycoproteins that present lipid antigens at the cell surface for immunological recognition by specialized
populations of T lymphocytes. Prior experimental data suggest a wide variety of lipid species can bind to CD1 molecules,
but little is known about the characteristics of cellular ligands that are selected for presentation. Here we have molecularly
characterized lipids bound to the human CD1d isoform. Ligands were eluted from secreted CD1d molecules and separated
by normal phase HPLC, then characterized by mass spectroscopy. A total of 177 lipid species were molecularly identified,
comprising glycerophospholipids and sphingolipids. The glycerophospholipids included common diacylglycerol species,
reduced forms known as plasmalogens, lyso-phospholipids (monoacyl species), and cardiolipins (tetraacyl species). The
sphingolipids included sphingomyelins and glycosylated forms, such as the ganglioside GM3. These results demonstrate
that human CD1d molecules bind a surprising diversity of lipid structures within the secretory pathway, including
compounds that have been reported to play roles in cancer, autoimmune diseases, lipid signaling, and cell death.
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Introduction
CD1 molecules are a family of b2-microglobulin associated
glycoproteins that present lipids and glycolipids at the cell surface
for recognition by T lymphocytes [1]. There are five CD1 isoforms
(CD1a, CD1b, CD1c, CD1d, and CD1e). Of these, the CD1d
isoform has attracted particular attention because it is the
restricting element for a subpopulation of T cells, called Natural
Killer T (NKT) cells, that has potent immuno-modulatory
properties [2]. In addition to recognizing certain microbial lipids,
NKT cells have been found to respond specifically to CD1d-
mediated presentation of endogenous cellular lipids [2]. However,
the self lipids recognized by human NKT cells remain poorly
characterized. Similarly, the molecular principles that govern the
selection of lipids that are presented by CD1d molecules for
immunological surveillance are not well understood.
Crystal structures of murine CD1d have been solved with a
variety of bound ligands, including glycosylated sphingolipids
(GSLs), phosphatidylcholine (PC), and a mannosylated form of
phosphatidylinositol (PI) [3–8]. Human CD1d molecules have
been crystallized bound to the glycosylated sphingolipid a-
galactosylceramide (a-GalCer) [9]. These analyses have revealed
that CD1d molecules have an overall structure resembling MHC
class I, but that their ligand binding groove is deeper and more
hydrophobic. Lipid ligands bind to CD1d with their hydrophobic
carbon chains largely buried within the binding groove, and their
polar head groups accessible at the molecular surface. The crystal
structures indicate there is some hydrogen bonding between the
CD1d molecule and features of the polar head groups of bound
ligands, however, it is not clear how much selection is exerted by
the CD1d molecule on the chemical nature of the ligand’s
head group. Nevertheless, it is clear from the crystallographic data
that a wide variety of polar head group structures can be
accommodated.
In contrast, hydrocarbon chains of bound lipids usually fit
snugly within the hydrophobic binding site. The CD1d ligand
binding site contains two major pockets, named A9 and C9 for
human CD1d [9] or A9 and F9 for murine CD1d [3], with the A9
pocket able to accommodate somewhat longer hydrocarbon
chains (approximately 26 carbons) than the C9/F9 pocket
(approximately 18 carbons). The crystallographic data suggest
that hydrocarbon chains containing multiple double bonds bind
preferentially in the A9 pocket where they can adopt a curved
conformation, whereas the C9/F9 pocket provides a more linear
configuration. However, biochemical analyses indicate that CD1d
molecules can bind a diverse array of ligands that include
substantial variation in radyl group structures [10–13]. The
stability of lipid binding to CD1d molecules has been related to the
length of the hydrocarbon chains and the manner in which they fill
the binding groove, with longer chains that fit well into the A9 and
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association [11]. Nevertheless, it is important to note that antigenic
lipids in which one of the hydrocarbon chains is severely truncated
can still bind to CD1d molecules in a sufficiently stable manner to
stimulate NKT cell responses [13,14].
Previous studies have identified glycosylated phosphatidylinosi-
tols (GPIs) and unmodified PI as major mammalian cellular
ligands of murine CD1d molecules [15,16]. Material eluted from
murine CD1d molecules that were purified from transfected insect
cells included mainly PC and phosphatidylethanolamine (PE) [7].
Cellular ligands bound to human CD1d molecules included PI
molecules with a variety of acyl chain structures [17]. However,
while individual murine and human NKT cells have been
identified that specifically recognize phospholipids such as PI
and PE as antigens presented by CD1d, NKT cells that recognize
these abundant phospholipids appear to be rare [18–20]. In
contrast, most murine NKT cells recognize a particular tri-
glycosylated sphingolipid called isoglobotrihexosylceramide
(iGb3), which may be a much less abundant component of the
pool of lipids presented by CD1d molecules since it is produced in
lysosomes by degradation of a mature form that contains four
sugars [21]. It is not clear whether iGb3 is also a self antigen for
human NKT cells since humans lack the enzyme required to
synthesize this compound [22], however it seems likely that the self
antigens that stimulate human NKT cells may also be minor
components of the pool of cellular ligands presented by human
CD1d molecules. Thus, a high-resolution analysis of the ligands
bound to human CD1d is critical for identifying compounds of
interest that may regulate human NKT cell responses. Addition-
ally, such an analysis would provide information about the
structural characteristics of lipid species that are naturally selected
for binding by CD1d. This information will be key for designing
new compounds that can be used therapeutically to modulate
immune responses by stimulating NKT cells, since such
pharmacological lipid antigens will need to be able to compete
effectively with endogenous lipids for binding to CD1d molecules
on antigen presenting cells.
Results
Secreted human CD1d molecules (sCD1d) were generated by
truncating the transmembrane and cytoplasmic domains, and
were expressed in the HLA class I deficient human lymphoblastoid
cell line 721.221 [23,24]. The cells were grown in hollow-fiber
bioreactors and approximately 25 mg of sCD1d was purified by
affinity chromatography. Bound ligands were released and
separated from the sCD1d molecules by employing a chloro-
form:methanol:water extraction protocol similar to that previously
described by Bligh and Dyer [25]. The eluted material was further
purified by normal phase HPLC, resulting in the fractionation of
various classes of lipids within the ligand pool (Figure 1A).
Fractions from the HPLC purification were subject to mass
spectrometry (MS) in both positive and negative ion modes,
generating ion maps of the compounds within each fraction
(Figure 1B). Individual ion peaks from these maps were further
analyzed by MS/MS, producing fragmentation patterns that
allowed structural identification of the major species in the peak by
comparison to previously published data and analysis of synthetic
lipid standards (Figures 1C and 1D).
Types of lipids bound by CD1d
Lipids found within the sCD1d ligand pool varied in the
backbone structure of the lipid and the nature of the lipid head
group, and in the numbers, types, chain lengths and degree of
unsaturation of the radyl groups. Two major categories of lipids
were present: glycerophospholipids and sphingolipids (Figure 2).
Within the glycerophospholipid category, three types of radyl
group configurations were identified: diradyl species (i.e. contain-
ing two carbon chains) were predominant, but monoradyl lyso-
phospholipids and tetraradyl cardiolipins were also found
(Figure 2A). The diradyl species included common diacylglycerol
phospholipids, as well as more unusual reduced forms called
plasmalogens (Figure 2A). A variety of polar head groups were
found among the glycerophospholipid species in the ligand pool
(Figure 2B), including unmodified phosphatidic acid (PA),
phosphatidylglycerol (PG), phosphatidylserine (PS), and species
that have been previously identified in biochemical analyses as
CD1d ligands such as PI, PE, and PC [7,15–17]. Three classes of
sphingolipid were also present in the ligand pool: sphingomyelin
(SM), and glycosylated sphingolipids (GSL) containing either
neutral or acidic modifications (Figure 2B). The sphingolipids
included derivatives of sphingosine (i.e. ceramides) as well as forms
derived from the structurally related base sphinganine. Notably,
we were not able to determine the structures of a number of ions
visible on the MS maps. These undetermined species may account
for up to one-quarter of the ligand pool.
Characteristics of lipid tails
The diversity of lipid head group structures found within the
ligand pool is consistent with this feature exerting little influence
on selection for binding to CD1d. In contrast, structural
characteristics of the radyl groups of lipids are thought to play a
major role in lipid binding to CD1 molecules. Previous
crystallographic studies have suggested that in order to fit into
the A9 and C9 pockets of CD1d molecules the carbon chains of
diacylated lipids should not be longer than C26 and C18,
respectively. To gain insight into the characteristics of lipids
selected for binding to human CD1d, we analyzed the length and
numbers of double bonds of carbon chains from diacylated ligand
species. A total of 149 species were included in the analysis. Sn-1
chains ranged from 12–22 carbons and contained from 0–7
double bonds (Figure 3A). Most sn-1 chains (62%) were 16–18
carbons long and contained zero or one unsaturation (Figure 3A).
Sn-2 chains ranged from 14–24 carbons and contained 0–6 double
bonds (Figure 3B). Similar to the sn-1 chains, most sn-2 chains
(58%) were 16–18 carbons with zero or one double bond
(Figure 3B). In both cases, there was a tendency for chains longer
than 18 carbons to contain at least one double bond, and
particularly among the sn-1 chains there was a clear positive
correlation between longer chain lengths and higher numbers of
double bonds (Figures 3A and 3B).
Based on the sizes of the A9 and C9 pockets observed in the
human CD1d crystal structure [9], it might be predicted that
diacylated lipids having both radyl chains longer than 18 carbons
would not fit well into the CD1d binding site. Our data is quite
consistent with this prediction, since out of 179 species that were
molecularly characterized, only four had two chains longer than
18 carbons (i.e. C20:3/C20:3 PA, C20:4/C20:3 PA, C20:3/C20:3
PI, and C20:3/C20:4 PI), and in these cases the chains were only
20 carbons long and all contained 3 or more double bonds. With
the exception of these four ligands, sn-1 or sn-2 chains longer than
C18 were always paired with chains that were 18 carbons or less
(Figure 3C). A comparison of the number of double bonds in each
chain revealed that fully saturated lipids were rare in the CD1d
ligand pool (4%), and species that contained one double bond in
each chain were the most frequent type, comprising 46% of the
total (Figure 3D). Sn-1 and sn-2 chains that contained two or more
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or one double bond (Figure 3D).
Unexpected species: plasmalogens, cardiolipins, and
lyso-phospholipids
Previous biochemical analyses have suggested that common
diacylglycerol phospholipids are major cellular ligands of CD1d
[7,15–17], but have provided little insight into less common ligands.
Our high-resolution analysis permitted identification of a number of
interesting but less abundant ligands of human CD1d. For example,
we observed that a significant number of plasmalogen derivatives
were included among the glycerophospholipids. These compounds
contain either an ether (-CH2-CH2-O-) or vinyl ether (-CH=
CH-O-) linked to the glycerol backbone at the sn-1 position instead
of the usual ester (R
1CO2-) linkage (Figure 2A), and are thought
play a number of specialized biological roles [26]. Almost half of the
PE species characterized fit into this category (21 out of the 43 total
species of PE), while plasmalogen forms were uncommon among
the other types of glycerophospholipids (1 PA, 1 PC, 1 PS, and 2 PI
plasmalogens were found). Figure 4 shows MS/MS results
identifying two PE plasmalogen ether species.
Cardiolipins are glycerophospholipids that are abundant in
mitochondrial membranes, and are essentially composed of two
phosphatidylglycerols linked together at the head group
(Figure 2A). As the previously characterized CD1d ligands are
mainly diacylated lipids, these tetraradyl compounds may seem
Figure 1. Isolation and characterization of ligands bound to human CD1d molecules. Secreted CD1d molecules were isolated by affinity
chromatography and subject to organic extraction followed normal phase chromatographic separation (HPLC), and mass spectrometry (MS). A) HPLC
chromatogram of extracted material. The general categories of lipids found along the profile are indicated using the following abbreviations: GSL,
glycosphingolipid; PE, phosphatidylethanolamine; CL, cardiolipin; PA, phosphatidic acid; PG, phosphatidylglycerol; PI, phosphatidylinositol; PS,
phosphatidylserine; GM3, ganglioside GM3; PC, phosphatidylcholine; SM, sphingomeylin. B) A section of MS ion map of fraction 26 in the negative
ion mode. Ions were manually selected for MS/MS fragmentation. Within this section of the ion map three lipids were characterized, as shown by the
labels above the corresponding peaks. C) MS/MS fragmentation pattern of one of these lipids, ion m/z 861. The [M2H]
2 of ion 861 provides ions m/z
597 [M2H2C16H31CH=C=O]
2 (the loss of the 18:1 ketene), m/z 579 [M2H2C17H33CO2H]
2 (the loss of the 18:1 carboxylic acid), m/z 417
[M2H2C16H31CH=C=O2Ins]
2 (the loss of the 18:1 ketene and inositol), m/z 281 [C17H33CO2]
2, (18:1 fatty acid), m/z 241 [Ins-PO32H2O]
2
(dehydrated inositol phosphate). D) MS/MS fragmentation pattern of synthetic PI (18:1/18:1).
doi:10.1371/journal.pone.0005325.g001
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cardiolipins were present in the CD1d ligand pool, and structurally
identified five species (Figure 5A). Shown in Figure 5B is the MS/
MS fragmentation pattern of a cardiolipin ion from fraction 18 of
the HPLC separation of the CD1d ligand pool.
Recent data has suggested that lipids containing only one
hydrocarbon chain may serve as ligands for CD1d, and may thus
stimulate T cell responses [14,27,28]. A lyso-derivative of the
central nervous system lipid sulfatide was found to be recognized
by a CD1d-restricted murine T cell line, and lyso-phosphatidyl-
choline (LPC) was reported to be recognized by CD1d-restricted T
cells that are expanded in the blood of human multiple myeloma
patients [27,28]. In this analysis we found a considerable number
of lyso-derivatives in the CD1d ligand pool (Figure 6A). Figure 6B
shows the MS/MS pattern identifying a species of LPC. The radyl
groups of the lyso-derivatives in the CD1d ligand pool showed a
similar distribution of carbon chain lengths and double bonds to
those of the sn-1 chains of the diacylated lipid species, although
carbon chains shorter than C16 were not observed among the
lyso- species (Figure 6C).
Glycosylated lipids
Most of the compounds that have been found to be antigens for
CD1d-restricted T cells are glycolipids [29]. Thus cellular
glycolipids that are presented by CD1d molecules are of great
interest. Several glycosylated lipids were identified within the
ligand pool, all of which were GSLs containing oligosaccharides
attached to a ceramide backbone (Figure 7A). The most abundant
of these was identified as a derivative of the ganglioside GM3 by
employing MS analysis before and after enzymatic digestion. The
MS ion map of fraction 33 from the normal phase HPLC
separation of the CD1d ligand pool revealed one major species
(Figure 7B). Sialidase S treatment of fraction 33, which specifically
releases terminal a(2-3)-linked sialic acids from a complex
carbohydrate, resulted in the formation of ions produced by the
cleavage of sialic acid from the parent compound (Figure 7C). The
MS/MS fragmentation pattern of the ion from fraction 33 showed
the distinctive initial loss of sialic acid followed by the stepwise loss
of two hexoses, and also delineated ions corresponding to the
ceramide backbone (Figure 7D). The MS/MS fragmentation
pattern after sialidase S treatment showed the same stepwise loss of
the remaining two hexoses (Figure 7E). The structural assignment
of the ion from fraction 33 as a derivative of GM3 was confirmed
by comparing it to the MS/MS fragmentation pattern of a purified
GM3 standard (data not shown).
Additionally, three neutral GSLs were found in the CD1d
ligand pool (Figure 7A). Two of these were assigned as di-
hexosylceramides and the third as a tri-hexosylceramide based on
their MS/MS fragmentation patterns, which clearly showed the
sequential loss of all the hexoses to yield the ceramide (data not
shown). We were not able to definitively determine the identities of
the sugars found in these GSLs or the chemistry of their linkages.
Also undetermined was whether glycosylphosphatidylinositols
(GPIs) were present in the ligand pool. A previous analysis
identified GPIs as a major constituent of the cellular ligands bound
to murine CD1d [16], and thus this may also be a natural ligand of
human CD1d molecules. It is worth noting that much of the
material within the human CD1d ligand pool that we were not
able to identify appeared to be of relatively high molecular weight,
and therefore it is possible that more glycosylated ligands are
present, and that these may include GPIs.
Discussion
Like MHC class I molecules, CD1d molecules are synthesized
in the endoplasmic reticulum (ER) and then follow the secretory
route through the Golgi and out to the cell surface [30]. However,
similar to MHC class II molecules, CD1d molecules are re-
internalized from the cell surface and traffic through the
Figure 2. Overview of the diversity of lipids identified in the CD1d ligand pool. A total of 177 molecular species were identified. The
majority of lipids characterized were phospholipids, but sphingolipid species were also identified. A) Tree diagram showing the categories and
structural characteristics of lipids found within the ligand pool. B) Tree diagram showing the diversity of lipid head groups. Lipid classes are
abbreviated as described in the legend for figure 1A. Numbers in parentheses represents the number of lipid species (i.e. radyl group carbon chain
variations) characterized in that subcategory.
doi:10.1371/journal.pone.0005325.g002
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[30]. Thus, CD1d molecules may acquire ligands in the secretory
pathway, or within the endosomal system, or while they are on the
cell surface. Since the secreted CD1d molecules that we have
analyzed here traffic through the secretory pathway but not
through the endosomal vesicular system, the pool of ligands bound
to these CD1d molecules may not encompass all of those
presented by wild type cell surface CD1d molecules. However,
we have found that in contrast to the murine system, endosomal
trafficking of human CD1d molecules is not required to stimulate
autoreactive responses from human NKT cells [31]. Therefore,
antigens that can activate human NKT cells are likely to be
present among the cellular CD1d ligands identified in this analysis.
Consistent with this, we show in a companion manuscript (see Fox
et al., submitted concurrently) that many human NKT cells
recognize LPC, a lipid that we show here was present in the CD1d
ligand pool.
It is a concern that non-physiological lipids derived from the
culture medium used to grow the human lymphoblastoid cells may
load into the secreted CD1d molecules and thus become part of
the ligand pool analyzed here. To address this point, we performed
an extraction of a sample of the fetal bovine serum (FBS) that is
diluted into a nutrient solution to make up the culture medium,
and analyzed the lipids by HPLC and MS. The HPLC profile of
Figure 3. Structural characteristics of radyl group carbon chains. Analysis of the length and degree of unsaturation of the carbon chains of
diradyl lipid species identified within the ligand pool. The sizes of the circles are proportional to the number of lipid species at each set of
coordinates. A total of 149 lipid species were included in the analysis. A) Analysis of sn-1 carbon chains, comparing the number of double bonds to
the length. B) Analysis of sn-2 carbon chains, comparing the number of double bonds to the length. C) Comparison of the lengths of the sn-2 versus
sn-1 carbon chains. D) Comparison of the number of double bonds in the sn-2 versus sn-1 carbon chains.
doi:10.1371/journal.pone.0005325.g003
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the CD1d ligand pool (see Figure S1), however MS analysis of
fractions containing these peaks did not show any species in
common (data not shown). This supports the conclusion that the
ligands identified here were derived from the human lymphoblas-
toid cells used to produce the secreted CD1d molecules.
By characterizing a large number of molecular species within
the CD1d ligand pool, our analysis provides new insights into the
structural characteristics of ligands that are selected for binding to
human CD1d. One area of interest concerns how the structural
features of lipids influence their positioning within the binding site.
Crystal structures of sphingolipids bound to murine or human
Figure 4. Identification of plasmalogens. A fraction of the diradyl phospholipid species within the CD1d ligand pool were identified as
plasmalogens, as exemplified by the mass spectrometry data shown here. A) Table summarizing the types of plasmalogen phospholipids identified.
B) Negative ion MS/MS of two PE ether plasmalogen species (m/z 726.7), from the MS ion map of Fraction 9. Only the carboxylate ion was
characterized. Ions m/z 462 and m/z 444 result from the loss of the 18:1 ketene and the 18:1 carboxylic acid respectively; ions m/z 436 and m/z 418
result from the loss of the 20:2 ketene and the 20:2 carboxylic acid respectively. The molecular formulas for the resulting ether moieties was deduced
from the mass of the [M2H2ketene]
2 and [M2H2RCO2H]
2 ions. The structures of the ether moieties were not unequivocally determined. They
could be plasmenyl or plasmanyl radyl groups.
doi:10.1371/journal.pone.0005325.g004
Figure 5. Identification of cardiolipins. Cardiolipins, which are tetraradyl dimers of phosphatidylglycerol, were present in the CD1d ligand pool.
A) Table summarizing the cardiolipin species identified. B) Negative ion MS/MS of ion m/z 713.5 from the MS ion map of Fraction 18, containing
cardiolipin (18:1/16:1)/(18:1/18:1). The map shows m/z 713.5 [M22H]
22, m/z 1173.8 [M22H2C15H29CO2]
2, m/z 1145.8 [M22H2C17H33CO2]
2, m/z 581
[(713.5622C16H31CH=C=O)/2]
22, m/z 417 (loss of FA from sn-2 and sn-1 positions of 18:1/18:1 PA structure and the sn-1 position of 18:1/16:1 PA
structure), m/z 389 (loss of FA from sn-2 position of 18:1/16:1 PA structure).
doi:10.1371/journal.pone.0005325.g005
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in the A9 pocket and the sphingosine chain is bound in the C9/F9
pocket [3–6,9]. This lipid orientation appears not to be
determined by the relative lengths of the two chains, since lipids
containing very short fatty acyl chains are positioned in the same
orientation as those in which it is longer. However, comparison of
the two crystal structures of CD1d molecules containing bound
phospholipids suggests that these ligands can bind in either of two
orientations [7,8]. In one case (murine CD1d with bound PC) the
sn-1 chain, which is 12 carbons long, is bound in the F9 pocket and
the sn-2 chain, which is 24 carbons long, is bound in the A9 pocket.
In the other case (murine CD1d with mannosylated PI) the
orientation of the lipid is flipped: the 16 carbon sn-1 chain binds in
the A9 pocket, and the sn-2 chain, also 16 carbons long, binds in
the F9 pocket. Assuming that the total hydrocarbon chain length
that can fit into the C9/F9 pocket is about 18 carbons, our data is
consistent with the possibility that phospholipids can bind in either
orientation, since lengths greater than 18 carbons were observed
for both the sn-1 and sn-2 chains, suggesting that either one can be
placed in the larger A9 pocket. Moreover, longer sn-1 or sn-2
chains were almost always paired with chains of 18 carbons or less,
which is consistent with a requirement for the other chain to fit in
the C9 pocket. Considering that the orientation of the lipid within
the CD1d binding site is likely to affect the positioning of the head
group, these data suggest the surprising possibility that a single
type of phospholipid might present two different epitopes for TCR
recognition depending on the orientation of binding within the
CD1d groove.
Another area of interest is the range and diversity of ligand
species presented for immune surveillance by CD1d molecules.
Our data indicate that human CD1d molecules bind several
unexpected types of lipids within the secretory pathway, and these
observations have a number of interesting implications. For
example, we found that plasmalogen ethers, particularly of PE,
accounted for a considerable fraction of the total diacylglycerol
phospholipid species. Plasmalogens have been found to play an
important role in maintaining proper cellular membrane func-
tioning and in preventing oxidative damage [26,32]. Because of
their ether structure plasmalogens are more acid labile than other
glycerophospholipids, and therefore they may be more likely to
undergo cleavage within CD1d molecules if transported to acidic
endosomal compartments. This might cause them to be more
easily removed and replaced by other lipids, or might create new
antigenic epitopes if lyso-phospholipid cleavage products remain
bound to CD1d.
The finding that cardiolipins were present within the CD1d
ligand pool was surprising for two reasons. First, it is not clear how
such tetraradyl species would bind to a single CD1d molecule, as
the crystallographic data suggest there is only room for two
hydrocarbon chains within the binding groove. We speculate that
cardiolipins may bind concurrently to two CD1d molecules and
thus ligate them together, though further analysis will be required
to determine this. The second surprising aspect of this observation
is that cardiolipins are confined almost entirely to the inner
membrane of the mitochondria where they are synthesized from
diacylated precursor phospholipids [33], and therefore their
presence in the CD1d ligand pool suggests that they are
transported from mitochondria to a location that permits loading
into CD1d molecules, such as the ER. Notably, the finding that
CD1d molecules may access lipids from mitochondria is consistent
with a previous survey of peptide ligands eluted from the MHC
class I molecule HLA-B*1801, in which we found that a number of
endogenously loaded peptides were derived from proteins
localized to the mitochondria [34]. Thus, much like their classical
HLA relatives, CD1d molecules survey ligands that originate in
diverse intracellular compartments.
It is also significant that we identified a number of lyso-
phospholipids within the CD1d ligand pool. Lyso-phospholipids,
particularly LPC, are key signaling molecules generated by
enzymatic cleavage of PC by phospholipase A2 molecules, and
Figure 6. Identification of lysophospholipids. A variety of lyso-phospholipids (i.e. monoradyl species) were found in the CD1d ligand pool. A)
Table summarizing the types of lyso-phospholipids identified. B) Negative ion MS/MS of ion m/z 556.5 from ion map of Fraction 36, containing the
chloride ion adduct of C18:1/C0:0 PC (lyso-PC or LPC). Ion m/z 556 [M+Cl]
2, gives rise to m/z 506 from the neutral loss of chloromethane
([M+Cl]
22CH3Cl). The fatty acid 18:1 is indicated by the ion m/z 281. C) Analysis of the carbon chains of the identified lyso-phospholipid species for
the number of double bonds compared to chain length.
doi:10.1371/journal.pone.0005325.g006
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most abundant species was identified as the ganglioside GM3 (see Figure 1A). Additionally, three glycosylated ceramides were found. A) Table
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indicator of cellular signaling responses. However, given that the
length and structure of the hydrocarbon chains of lipids have been
shown to be critical for their stable binding to CD1d molecules
[11], and lyso-phospholipids only have a single carbon chain, it is
perhaps surprising that that lyso-phospholipids are able to
compete effectively with diacylated species for binding to CD1d.
Further studies will be required to determine the relative binding
affinity of lyso-phospholipids for CD1d, and whether there are
specific mechanisms that contribute to the intracellular loading of
these lipids.
We also found several glycosylated lipids in the ligand pool,
including the terminally sialated species GM3. Since maturation of
glycans and terminal sialation occur within the Golgi compart-
ments, this finding suggests either that CD1d molecules can load
lipid antigens in the Golgi, or that glycans of CD1d-bound ligands
can be modified in the Golgi. Interestingly, two of the glycosylated
lipids we identified are tri-hexosylated sphingolipids that bear
resemblance to iGb3, a compound identified as a major self
antigen for murine NKT cells [21]. We identified the major tri-
hexosylated species in the ligand pool as GM3, a compound that
does not appear to be highly antigenic for NKT cells [35], but the
exact identity of the other species remains undetermined. One of
the key antigenic features of iGb3 is that the terminal sugar, a
galactose, is linked to the next sugar in an a-anomeric
configuration [21]. Humans and other great apes appear during
evolution to have lost the glycosyl transferase enzymes required for
biosynthesizing this type of glycan on proteins, and it has recently
been demonstrated that we also lack a functional iGb3 synthase
gene required to synthesize this glycolipid [22]. Hence, despite its
possible structural similarity to iGb3, it seems unlikely that the
unidentified tri-hexosylated GSL contains the antigenic feature of
a terminal galactose residue in an a-linkage.
In conclusion, the results presented here demonstrate that
natural cellular ligands of human CD1d molecules include a
remarkable variety of lipids. In addition to roles in normal cellular
functioning, lipids found in the CD1d ligand pool have been
specifically associated with immune recognition in disease. Several,
including CL, PE, PI, and gangliosides, are targets of autoanti-
bodies in human autoimmune diseases, and cell surface ganglio-
sides on neoplastic cells can also be targeted by specific antibodies.
Thus, an important area for future investigation is to understand
how the CD1d-mediated presentation of cellular lipids relates to
the immunological targeting of these lipids during disease
pathogenesis.
Materials and Methods
Generation of secreted human CD1d molecules
To produce secreted CD1d (sCD1d), the cDNA of human
CD1d (Genbank accession number NM_001766) was modified by
deleting the transmembrane and cytoplasmic domains, and a 30
base-pair tail encoding the 10 amino acid sequence
SVVSTDDDLA corresponding to the rat very low density
lipoprotein receptor (VLDLr) was added to facilitate purification
[36]. sCD1d-VLDLr was cloned into the mammalian expression
vector pcDNA3.1 (Invitrogen) and then sequenced to ensure
fidelity. The construct was transfected into the HLA class I
deficient human B cell line 721.221 as previously described [37].
Transfectants were cultured in an AcuSyst-Maximizer hollow-
fiber bioreactor unit (Biovest International, 8500 Evergreen
Boulevard, Minneapolis, MN 55433–6000) in RPMI 1640, 10%
FBS and 1% penicillin/streptomycin. Cells were monitored for
glucose and oxygen consumption. Supernatants containing
approximately 25 mg of sCD1d-VLDLr were collected for further
analysis.
Extraction and purification of bound ligands
Clarified supernatant was affinity purified over a Sepharose Fast
Flow 4B matrix (Amersham-Pharmacia Biotech, Piscataway, NJ)
that was coupled to anti-VLDVr antibody. Bound material was
washed with 20 mM sodium phosphate buffer (pH 7.2) and then
eluted with 0.2 M acetic acid, pH 2.7, and lyophilized. Ligands
were extracted from the CD1d molecules using the chloroform/
methanol/water method described by Bligh and Dyer [25]. Lipid
classes were separated by normal phase-HPLC (Luna 3 m Silica (2)
100 A ˚, 15062 mm column, Phenomenex, Torrance, CA) using a
gradient of n-hexane:2-propanol:water (41:54:5 v/v) and n-
hexane:2-propanol:water (37:54:9 v/v), as previously described
[38]. Fractions of 200 mL were collected at 1.0 min intervals and
monitored by UV absorption at 210 nm.
Mass spectrometric analysis
The HPLC fractions were sprayed via nanoESI on a Q-STAR
quadrupole mass spectrometer with a TOF detector and nanoESI
ionization source (PerSceptive SCIEX, Foster City, CA), gener-
ating lipid ion maps for each fraction in the range of 350–
2000 amu. Ion maps were obtained in both positive and negative
ion modes. Ions were manually selected for MS/MS analyses from
these ion maps. Lipid structures were determined with the aid of
Lipid Maps (www.lipidmaps.org) and published MS studies of
phospholipids [39–48], sphingomyelins and ceramides [49–51],
and gangliosides [52–55]. Representative synthetic lipids corre-
sponding to each class of lipid were purchased from Avanti Polar
Lipids (Alabaster, AL) and subjected to MS/MS under identical
collision conditions as the naturally occurring lipid.
Sialidase treatment
Fraction 33 from the HPLC separation of the CD1d ligand pool
was dissolved in aqueous buffer and subject to digestion with
sialidase S (Prozyme, San Leandro, CA) according to the
manufacturer’s protocol. The reaction was then quenched with
chloroform, and lipids were extracted from the aqueous phase
using chloroform/methanol/water. MS analysis was performed on
the organic layer.
Supporting Information
Figure S1 HPLC analysis of fetal bovine serum. Fetal bovine
serum (FBS) or a preparation of affinity purified CD1d were
organically extracted according to the method of Bligh and Dyer
summarizing the glycosylated lipid ligands identified. B) The most abundant species, fraction 33 of the normal phase HPLC separation, was subject to
further characterization by enzymatic digestion and mass spectrometry. Shown is the partial negative ion MS map of fraction 33. C) Partial negative ion
MSmapoffraction33afterSialidaseStreatment.Notetheformation ofionsresultingfromthecleavageofsialicacidfromtheparentcompound.D)MS/
MS fragmentation of ion m/z 1262 [M2H]
2 from panel A. The fragmentation pattern shows the loss of sialic acid, m/z 970 [M2sialic acid]
2, m/z 808
[M2sialic acid2hexose]
2, m/z 790 [M2sialic acid2hexose2H2O]
2, m/z 646 [M2sialic acid2hexose2hexose]
2, m/z 406 [C26H48NO2]
2 (N-acyl
chain+carbons 1 and2 of LCB). E) Negative ionMS/MS fragmentation of ion m/z 1006 [M+Cl]
2 from panel C. Thefragmentation pattern showsthatafter
enzymatic cleavage of the sialic acid residue, the remaining two sugar residues are lost in an identical fashion to that of the GM3 species in Panel D.
doi:10.1371/journal.pone.0005325.g007
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PLoS ONE | www.plosone.org 9 May 2009 | Volume 4 | Issue 5 | e5325[25]. The resulting material was separated by normal phase
HPLC, resulting in the top trace for the CD1d preparation and
the bottom trace for the FBS. The fractions from all peaks that
overlapped in the two profiles were analyzed by MS. None of the
lipids found in the CD1d fractions were detected in FBS fractions
of the corresponding peaks (data not shown), indicating that the
CD1d lipids did not derive from the FBS.
Found at: doi:10.1371/journal.pone.0005325.s001 (0.24 MB TIF)
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